Overview
Sweden life sciences investor's Q1 net sales rose 13% yr/yr, driven by organic growth and acquisitions
Adjusted EBITA for Q1 grew 30%, with margin rising to 19.7%
Company says all business areas contributed to growth, with MedTech showing strong organic gains
Outlook
Company expects gradual margin improvement in Specialty Pharma in H2 and coming years
MedCap says conditions for acquisitions remain favourable and plans to continue completing deals
Company says external uncertainty has not materially impacted sales but remains cautious about indirect effects
Result Drivers
MEDTECH ORGANIC GROWTH - Co said MedTech segment delivered solid organic net sales growth, with nutrition and ECG vacuum systems standing out
ACQUISITIONS - Acquisitions contributed to growth in Assistive Tech and Specialty Pharma, with XGX Pharma acquisition driving Specialty Pharma net sales
FAVOURABLE PRODUCT MIX - Favourable product mix in Abilia and the acquisition of LivAssured contributed positively to Assistive Tech performance
Company press release: ID:nMFN91bLf4
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 556.60 mln
Q1 EPS
SEK 3.70
Q1 Net Income
SEK 55.70 mln
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the investment management & fund operators peer group is "buy"
Wall Street's median 12-month price target for MedCap AB (publ) is SEK621.50, about 33% above its April 28 closing price of SEK467.40
The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 28 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)